The invention relates to novel chimeric antibiotics of formula (I) wherein R<；SUP>；1<；/SUP>； represents OH, OPO<；SUB>；3<；/SUB>；H<；SUB>；2<；/SUB>； or OCOR<；SUP>；5<；/SUP>；； R<；SUP>；2<；/SUP>； represents H, OH or OPO<；SUB>；3<；/SUB>；H<；SUB>；2<；/SUB>；； A represents N or CR<；SUP>；6<；/SUP>；； R<；SUP>；3 <；/SUP>； represents H or fluorine； R<；SUP>；4<；/SUP>； is H, (C<；SUB>；1<；/SUB>；-C<；SUB>；3<；/SUB>；) alkyl, or cycloalkyl； R<；SUP>；5<；/SUP>； is the residue of a naturally occurring amino acid, of the enantiomer of a naturally occurring amino acid or of dimethylaminoglycine； R<；SUP>；6<；/SUP>； represents H, alkoxy or halogen； and n is O or 1； and to salts (in particular pharmaceutically acceptable salts) of compounds of formula (I). These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).
